{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:40:50Z","timestamp":1767984050338,"version":"3.49.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.bioorg.2025.108317","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T19:34:58Z","timestamp":1741030498000},"page":"108317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Characterization of new non-ATP dependent inhibitors of TLK1 as potential molecules for treating prostate cancer"],"prefix":"10.1016","volume":"158","author":[{"given":"Delna","family":"Johnson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivangi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Thiruvenkatam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivapriya","family":"Kirubakaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.108317_bb0005","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2020"},{"issue":"7","key":"10.1016\/j.bioorg.2025.108317_bb0015","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jama.1946.02870240008003","article-title":"Prostatic cancer treated by orchiectomy: the five year results","volume":"131","author":"Huggins","year":"1946","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2025.108317_bb0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.bioorg.2025.108317_bb0025","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2025.108317_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013500","article-title":"Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models","volume":"5","author":"Marques","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bioorg.2025.108317_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/eem.11.33","article-title":"Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer","volume":"6","author":"Knudsen","year":"2011","journal-title":"Expert. Rev. Endocrinol. Metab."},{"key":"10.1016\/j.bioorg.2025.108317_bb0040","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.bioorg.2025.108317_bb0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of Care in Castration Resistant Prostate Cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108317_bb0050","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ijc.32200","article-title":"Targeting the TLK1\/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors","volume":"145","author":"Singh","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2025.108317_bb0055","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1104\/pp.103.038117","article-title":"TOUSLED kinase activity oscillates during the cell cycle and interacts with chromatin regulators","volume":"134","author":"Ehsan","year":"2004","journal-title":"Plant Physiol."},{"key":"10.1016\/j.bioorg.2025.108317_bb0060","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1038\/ncomms4394","article-title":"Tousled-like kinases phosphorylate Asf1 to promote histone supply during DNA replication","volume":"5","author":"Klimovskaia","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2025.108317_bb0065","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1101\/gad.276703","article-title":"Tousled-like kinase functions with the chromatin assembly pathway regulating nuclear divisions","volume":"17","author":"Carrera","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.bioorg.2025.108317_bb0070","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00268-008-9840-1","article-title":"DNA damage response pathways in tumor suppression and Cancer treatment","volume":"33","author":"Liang","year":"2009","journal-title":"World J. Surg."},{"key":"10.1016\/j.bioorg.2025.108317_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2199-5-1","article-title":"Translation of the radioresistance kinase TLK1B is induced by gamma-irradiation through activation of mTOR and phosphorylation of 4E-BP1","volume":"5","author":"Sunavala-Dossabhoy","year":"2004","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108317_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101474","article-title":"Generation of phenothiazine with potent anti-TLK1 activity for prostate Cancer therapy","volume":"23","author":"Singh","year":"2020","journal-title":"Iscience"},{"issue":"13","key":"10.1016\/j.bioorg.2025.108317_bb0085","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.3390\/ijms241311100","article-title":"Targeting prostate cancer, the \u2018tousled way\u2019","volume":"24","author":"Bhoir","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.108317_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113904","article-title":"Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against tousled-like kinases","volume":"227","author":"Lee","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108317_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116357","article-title":"Discovery and optimization of narrow spectrum inhibitors of tousled like kinase 2 (TLK2) using quantitative structure activity relationships","volume":"271","author":"Asquith","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108317_bb0100","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41467-018-04941-y","article-title":"Molecular basis of tousled-like kinase 2 activation","volume":"9","author":"Mortuza","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108317_bb0105","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/9035","article-title":"Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases","volume":"1","author":"Hoessel","year":"1999","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108317_bb0110","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/cimb45030117","article-title":"Novel phthalic-based anticancer tyrosine kinase inhibitors: design, synthesis and biological activity","volume":"45","author":"Kalinichenko","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108317_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.08.022","article-title":"New amide linked dimeric 1, 2, 3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors","volume":"29","author":"Deshmukh","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.108317_bb0120","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.108317_bb0125","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3390\/md8051526","article-title":"Halogenated indole alkaloids from marine invertebrates","volume":"8","author":"Pauletti","year":"2010","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.bioorg.2025.108317_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12867-016-0056-x","article-title":"TLK1B mediated phosphorylation of Rad9 regulates its nuclear\/cytoplasmic localization and cell cycle checkpoint","volume":"17","author":"Awate","year":"2016","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.bioorg.2025.108317_bb0135","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2019.03.041","article-title":"The TLK1-Nek1 axis promotes prostate cancer progression","volume":"453","author":"Singh","year":"2019","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108317_bb0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.dnarep.2008.09.005","article-title":"Tousled homolog, TLK1, binds and phosphorylates Rad9; TLK1 acts as a molecular chaperone in DNA repair","volume":"8","author":"Sunavala-Dossabhoy","year":"2009","journal-title":"DNA repair"},{"key":"10.1016\/j.bioorg.2025.108317_bb0145","series-title":"Fog Pharmaceuticals Inc. Collections of peptides, peptide agents, and methods of use thereof. U.S. Patent Application","first-page":"939","volume":"17(269)","author":"Mcgee","year":"2021"},{"issue":"5","key":"10.1016\/j.bioorg.2025.108317_bb0150","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bmc.2016.01.047","article-title":"Synthesis and cytotoxicity of thieno [2, 3-b] quinoline-2-carboxamide and cycloalkyl [b] thieno [3, 2-e] pyridine-2-carboxamide derivatives","volume":"24","author":"Leung","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108317_bb0155","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ejmech.2014.09.001","article-title":"Synthesis and cytotoxicity of thieno [2, 3-b] pyridine and furo [2, 3-b] pyridine derivatives","volume":"86","author":"Hung","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108317_bb0160","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1039\/C5MD00245A","article-title":"A synthesis, in silico, in vitro and in vivo study of thieno [2, 3-b] pyridine anticancer analogues","volume":"6","author":"Arabshahi","year":"2015","journal-title":"Med. Chem. Commun."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108317_bb0165","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1002\/jhet.3674","article-title":"Design, synthesis, antimicrobial evaluation, and laccase catalysis effect of novel benzofuran\u2013oxadiazole and benzofuran\u2013triazole hybrids","volume":"56","author":"Faiz","year":"2019","journal-title":"J. Heterocyclic Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108317_bb0170","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1039\/D2OB02191A","article-title":"Synthesis, kinetics and cellular studies of new phenothiazine analogs as potent human-TLK inhibitors","volume":"21","author":"Johnson","year":"2023","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108317_bb0175","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1038\/s41598-018-22744-5","article-title":"High yield bacterial expression, purification and characterisation of bioactive human tousled-like kinase 1B involved in cancer","volume":"8","author":"Bhoir","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.108317_bb0180","series-title":"QikProp, Schr\u00f6dinger, LLC, New York, NY","year":"2024"},{"key":"10.1016\/j.bioorg.2025.108317_bb0185","series-title":"LigPrep, Schr\u00f6dinger, LLC, New York, NY","year":"2024"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500197X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682500197X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T18:29:50Z","timestamp":1765218590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682500197X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"alternative-id":["S004520682500197X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108317","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of new non-ATP dependent inhibitors of TLK1 as potential molecules for treating prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108317"}}